ENTA—Mavyret US scripts—week ending 11/17/17 (according to IMS)….
TRx: 1161, +6.1% vs prior week NRx: 696, +2.7% vs prior week
We are now 16 weeks into the US launch.
(As previously noted, Mavyret’s absolute script numbers reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.